Drug Maker Lupin Inks Licensing Pact With Axantia For Pegfilgrastim

Drug Maker Lupin Inks Licensing Pact With Axantia For Pegfilgrastim

By, Admin 2 February 2022

Pegfilgrastim Is Indicated To Reduce The Duration Of Neutropenia And The Incidence Of Febrile Neutropenia In Patients Receiving Chemotherapy. Lupin Had Earlier Received The Usfda Acceptance For Review Of The Biologics License Application (Bla) For Its Proposed Biosimilar To Neulasta (Pegfilgrastim).Drug Maker Lupin On Tuesday Said It Has Inked A Licensing And Distribution Pact With Axantia For Pegfilgrastim, Used To Stimulate The Production Of White Blood Cells, In The Middle East And North Africa. The Mumbai-Based Drug Firm Has Entered Into A License, Supply And Technology Sharing Agreement With Axantia Holding, A Leading Pharmaceutical Company In The Middle East Region, Lupin Said In A StatementUnder The Terms Of The Agreement, Axantia Will Register, Distribute And Market Biosimilar Pegfilgrastim In Certain Territories Including Saudi Arabia, Certain Gcc Countries, Jordan, Lebanon, Iraq, Sudan, Libya And Algeria, It Added. Pegfilgrastim Is Indicated To Reduce The Duration Of Neutropenia And The Incidence Of Febrile Neutropenia In Patients Receiving Chemotherapy. Lupin Had Earlier Received The Usfda Acceptance For Review Of The Biologics License Application (Bla) For Its Proposed Biosimilar To Neulasta (Pegfilgrastim).

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!